Landmark HIFI Study Publication Demonstrates Positive Outcomes with Focal One® Robotic HIFU Versus Surgery in the Management of Prostate Cancer
04. Dezember 2024 09:10 ET
|
EDAP TMS S.A.
HIFI Study is the largest (N = 3,328) prospective, comparative, multi-center clinical study ever conducted comparing prostate cancer treatmentsPositive study results are expected to drive...
EDAP to Participate in the Piper Sandler 36th Annual Healthcare Conference
27. November 2024 07:00 ET
|
EDAP TMS S.A.
LYON, France, November 27, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced that Ryan Rhodes, Chief Executive Officer of EDAP TMS, is...
EDAP Announces Scientific Presentation Highlighting Feasibility of Focal One® to Perform Non-thermal Histotripsy Energy Delivery at the 187th Acoustical Society of America Meeting
22. November 2024 08:00 ET
|
EDAP TMS S.A.
Early feasibility work demonstrates Focal One system’s ability to generate histotripsy lesions ex vivo LYON, France, November 22, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in...
EDAP Announces Scientific Presentation at 2024 AAGL Global Congress Comparing Focal One HIFU Versus Surgery for the Treatment of Deep Infiltrating Endometriosis
19. November 2024 08:00 ET
|
EDAP TMS S.A.
Treatment with robotic HIFU showed reduction in moderate and severe post-operative complications and reduced hospital stay compared to surgery LYON, France, November 19, 2024 - EDAP TMS...
EDAP Reports Third Quarter 2024 Financial Results
07. November 2024 07:00 ET
|
EDAP TMS S.A.
Reported Q3 worldwide revenue of EUR 13.1 million (USD 14.4 million), increasing 11.6% over Q3 2023Reported Q3 worldwide HIFU revenue of EUR 4.5 million (USD 4.9 million), increasing 48.2%...
EDAP to Participate in the 2024 Jefferies London Healthcare Conference
06. November 2024 08:00 ET
|
EDAP TMS S.A.
LYON, France, November 6, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced that Ryan Rhodes, Chief Executive Officer, is scheduled to...
EDAP to Announce Third Quarter 2024 Financial Results on November 7, 2024
24. Oktober 2024 08:00 ET
|
EDAP TMS S.A.
Company to host conference call and webcast on Thursday, November 7th at 8:30am EDT LYON, France, October 24, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic...
EDAP Announces First Patients Treated in Phase I/II Study Evaluating Focal One Robotic HIFU for the Treatment of Benign Prostatic Hyperplasia (BPH)
01. Oktober 2024 07:00 ET
|
EDAP TMS S.A.
LYON, France, October 1, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first patients have been treated in a Phase I/II...
EDAP and Avenda Health Launch World’s First AI-Assisted Focal One® Robotic HIFU Procedures
19. September 2024 08:00 ET
|
EDAP TMS S.A.
First Unfold AI®-Assisted Focal One procedures successfully performed at the UCLA School of MedicineFDA-cleared Unfold AI enables urologists to...
EDAP to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
29. August 2024 08:00 ET
|
EDAP TMS S.A.
LYON, France, August 29, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced that Ryan Rhodes, Chief Executive Officer, is scheduled to...